Adial Pharmaceuticals (ADIL) Operating Expenses (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Operating Expenses of $2.0 million for Q1 2026, down 66.16% sequentially from $5.9 million in Q3 2025, and down 11.72% YoY from $2.3 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Operating Expenses (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Operating Expenses for 10 years, with the latest figure at $2.0 million in Q1 2026.
- Quarterly Operating Expenses fell 11.72% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 8.99% YoY) and the FY2025 annual result came in at $7.8 million, down 5.85% from the prior year.
- Operating Expenses declined to $2.0 million in Q1 2026 per ADIL's latest filing, from $5.9 million in the prior quarter.
- Over five years, Operating Expenses peaked at $6.3 million in Q3 2024 and troughed at $894649.0 in Q4 2023.
- A 5-year average of $2.6 million and a median of $2.3 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses plunged 65.56% in 2023, then surged 367.16% in 2024.
- Over 5 years, Operating Expenses stood at $2.6 million in 2022, then slumped by 65.56% to $894649.0 in 2023, then soared by 42.25% to $1.3 million in 2024, then surged by 364.72% to $5.9 million in 2025, then slumped by 66.16% to $2.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $2.0 million, $5.9 million, and $2.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 52.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00 Mn |
| Sep 30, 2025 | 5.91 Mn |
| Jun 30, 2025 | 2.82 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 6.34 Mn |
| Jun 30, 2024 | 1.92 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 894,649.00 |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | 2.27 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 2.55 Mn |
| Jun 30, 2022 | 3.24 Mn |
| Mar 31, 2022 | 3.06 Mn |
| Dec 31, 2021 | 5.98 Mn |
| Sep 30, 2021 | 4.06 Mn |
| Jun 30, 2021 | 4.40 Mn |
| Mar 31, 2021 | 4.84 Mn |